|
Leukopenia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A potential association between high 6-thioguanine nucleotides (6-TGN) or 6-methylmercaptopurine (6-MMP) levels and leukopenia was observed, since most studies reported higher metabolite levels in leukopenic patients (6-TGN: 204-308 (Lennard method) and 397 (Dervieux method), 6-MMP: 4020-10 450 pmol/8 x 10<sup>8</sup> RBC) compared to controls (6-TGN: 170-212 (Lennard method) and 269 (Dervieux method), 6-MMP: 1025-4550 pmol/8 x 10<sup>8</sup> RBC).
|
31342537 |
2019 |
|
Leukopenia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There was no significant difference of 6-TGN concentration between patients with or without leukopenia (<i>p</i> = 0.15) and no association was found in patients with <i>NUDT15 R139C</i> variants alleles (<i>p</i> = 0.62).
|
29867468 |
2018 |
|
Leukopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
T1 threshold 6-TGN concentrations of 213 pmol/8 × 10<sup>8</sup> erythrocytes and 3525 pmol/8 × 10<sup>8</sup> erythrocytes for 6-MMPR were defined: patients exceeding these values were at increased leukopenia risk (odds ratio [OR] 6.2 [95% CI: 2.8-13.8] and 5.9 [95% CI: 2.7-13.3], respectively).
|
27402913 |
2017 |
|
Leukopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
6-TGN measurement is a helpful method of preventing disease relapse and avoiding leukopenia in individual azathioprine maintenance therapy.
|
27152547 |
2016 |
|
Leukopenia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate the influence of NUDT15 R139C, thiopurine S-methyltransferase (TPMT), 6-TGN and 6-MMPR on thiopurine-induced leukopenia in Chinese patients with Crohn's disease.
|
27604507 |
2016 |
|
Leukopenia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
TPMT*3C had a specificity of 100%, but a sensitivity of 8% for predicting leucopenia.A 6-TGN level between 225 and 420 pmol/8 × 10(8) RBC could be a therapeutic window in patients receiving AZA therapy, and it could likely predict leucopenia in the initial 12 weeks of AZA therapy and a reasonable chance of successful clinical response in CD patients.
|
27082580 |
2016 |
|
Leukopenia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that NUDT15 R139C-related thiopurine-induced leukocytopenia is mediated by a 6-TGN-independent mechanism.
|
26590936 |
2016 |
|
Leukopenia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, there are factors other than increased 6-TGN levels that are involved in the onset of leukopenia.
|
26360046 |
2015 |
|
Leukopenia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Leukopenia (P = 0.025) and lymphopenia (P = 0.045) were associated with higher levels of 6-TGN.
|
25851563 |
2015 |
|
Leukopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
High levels of HPRT activity could be a predictor of leukopenia and unsafe 6-TGN concentrations in patients undergoing AZA/6-MP therapy.
|
21381155 |
2012 |
|
Leukopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Three patients with severe leukopenia and 10 patients with high 6-TGN concentrations had no thiopurine S-methyl transferase mutations.
|
18662197 |
2008 |
|
Leukopenia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Compared with wild types, TPMT heterozygotes had an 8.3-fold higher risk for 6-TGNs >450 pmol/8 x 10(8) erythrocytes (concentration associated with increased risk for leukopenia), but an 8.2-fold lower risk for 6-MMPNs >5700 pmol/8 x 10(8) erythrocytes (concentration associated with increased risk for hepatotoxicity).
|
16166171 |
2005 |
|
Leukopenia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TPMT genotype correlated with 6-TGN concentrations (0.576, P < 0.01), and patients with mutant alleles had a relative risk (RR) of 12.0 (CI95% 1.7-92.3) of developing leukopenia.
|
15167634 |
2004 |
|
Leukopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, three adult patients were studied who developed very high RBC 6-TGN concentrations and thiopurine-induced leukopenia.
|
3467886 |
1987 |